Physician profile
George Y Zureikat
NPI 1891765426
$172,676.08
in general payments reported to CMS, 2019-2025
22 companies · $45K in 2025
The $45K reported for 2025 was more than what 99% of Pediatric Critical Care Medicine providers received nationally (typical 2025 total: $71.68).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,310 · 2020: $7,180 · 2021: $15K · 2022: $11K · 2023: $62K · 2024: $30K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $93K · Consulting Fee: $17K · Travel and Lodging: $9,766 · Food and Beverage: $9,318 · Honoraria: $6,875 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,650 · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $92,886.25 |
| Consulting Fee | $16,787.50 |
| Travel and Lodging | $9,766.07 |
| Food and Beverage | $9,318.29 |
| Honoraria | $6,875.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,650.00 |
| Education | $287.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $111,782.03 | 2019-2025 | Xywav |
| Axsome Therapeutics, INC. | $25,238.44 | 2022-2025 | Sunosi, Symbravo |
| Harmony Biosciences LLC | $15,515.01 | 2020-2025 | Wakix |
| Idorsia Pharmaceuticals US INC | $15,032.61 | 2022-2024 | Quviviq |
| Inspire Medical Systems, INC. | $2,378.64 | 2019-2025 | Inspire |
| Amgen INC. | $664.09 | 2023-2025 | Tezspire |
| Astrazeneca Pharmaceuticals Lp | $570.13 | 2020-2025 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $352.37 | 2019-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $168.25 | 2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.35 | 2020-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $146.32 | 2023-2025 | Lumryz |
| Genzyme Corporation | $102.18 | 2025 | |
| Optinose US, INC. | $91.54 | 2021-2022 | |
| Zoll Respicardia, INC. | $91.34 | 2023-2024 | Remede System |
| Azurity Pharmaceuticals, INC. | $78.69 | 2024-2025 | Horizant |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 3b Medical, INC. | $75.85 | 2023-2025 | Luna |
| Vanda Pharmaceuticals INC. | $73.22 | 2020 | |
| Resmed Corp | $65.54 | 2019-2025 | |
| Lilly USA, LLC | $45.30 | 2025 | Zepbound |
| Novartis Pharmaceuticals Corporation | $19.80 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.66 | 2021 | |
| Phadia US INC. | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Zureikat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.